BioCorRx

BioCorRx Net Change in Cash

The Net Change in Cash of BioCorRx (BICX) as of Oct 20, 2026 is 51,327.00 USD. In the previous year, Net Change in Cash was 22,811.00 USD — a change of 125.01% (higher).

Net Change in Cash

51,327.00USD

YoY

125.01%

Last updated:

Net Change in Cash of BioCorRx is 2025 51,327.00 USD. Net Change in Cash of BioCorRx was 2024 22,811.00 USD. It decreases by 125.01% higher compared to the previous year.

The BioCorRx Net Change in Cash history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Change in Cash
Date
Net Change in Cash
Jan 1, 2018
268,430.00 USD
Jan 1, 2019
2.37 M USD
Jan 1, 2020
-2.05 M USD
Jan 1, 2021
-506,215.00 USD
Jan 1, 2022
-17,223.00 USD
Jan 1, 2023
-3,393.00 USD
Jan 1, 2024
22,811.00 USD
Jan 1, 2025
51,327.00 USD
The BioCorRx Net Change in Cash history
YEARNet Change in CashYoY
51,327.00USD+125.01%
22,811.00USD-772.30%
-3,393.00USD-80.30%
-17,223.00USD-96.60%
-506,215.00USD-75.35%
-2.05 MUSD-186.80%
2.37 MUSD+781.45%
268,430.00USD-304.73%
-131,113.00USD+2.75%
-127,605.00USD-176.44%
166,940.00USD-401.09%
-55,446.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BioCorRx Stock analysis

What does BioCorRx do? The company BioCorRx Inc is a US-American company that was founded in 2008 and is headquartered in Anaheim, California. BioCorRx specializes in the development and marketing of innovative treatment methods for alcohol and drug dependency. The history of BioCorRx began with the introduction of its flagship product, the BioCorRx Recovery Program, which is based on a novel medical technology called Naltrexone/Buprenorphine Implant. Unlike traditional methods of treating alcohol and drug addiction, which typically rely on medication and psychotherapeutic support, the BioCorRx Recovery Program is an implantable, long-term treatment system that continuously delivers the active ingredient Naltrexone or Buprenorphine into the patient's body. The idea behind this is that the active ingredients prevent withdrawal symptoms and thereby reduce the risk of relapse. In recent years, BioCorRx has expanded its product portfolio and expanded its business activities to new segments in order to further drive the company's growth. This includes, for example, the field of telemedicine services, which allow BioCorRx to offer its treatment technology and medical services through online communication. Telemedicine services such as virtual patient consultation or online group therapy programs are particularly in demand in times of COVID-19. Another focus of BioCorRx is the management of medical personnel. Studies have shown that good patient care and counseling heavily influence the success of treatment. BioCorRx has now also developed its own platform that eases and improves the management, training, and monitoring of medical staff. BioCorRx also utilizes the concept of franchise systems to market its products and services. The franchise system offers medical professionals and organizations working in the field of addiction treatment the opportunity to open their own BioCorRx clinic and offer the company's products and services in their local market. Each clinic is advised and supported by BioCorRx and must adhere to certain standards and quality criteria. In the future, BioCorRx plans to further diversify its product offering and develop new technologies to improve treatment options for alcohol and drug dependents. An example of such a technology is medication based on Ibogaine. BioCorRx has already started initial research in this direction and is actively working on pre-clinical studies. Overall, BioCorRx is a company that primarily focuses on innovative technologies for the treatment of addiction. The company has experienced substantial growth in recent years by expanding its product range and customer base, and focusing on the areas of telemedicine, personnel management, and franchise systems. With its forward-thinking technologies and strong emphasis on quality and patient satisfaction, BioCorRx is expected to continue playing an important role in addiction treatment in the years to come. BioCorRx is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioCorRx stock

Net Change in Cash of BioCorRx is 51,327.00 USD in 2025.

Net Change in Cash of BioCorRx changed from 22,811.00 USD to 51,327.00 USD, representing a 125.01% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Change in Cash BioCorRx since 2006 – with annual values, charts, and detailed analysis.

Net change in cash is the total change in cash and equivalents during the period, combining operating, investing, and financing cash flows.

Net Change in Cash's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Change in Cash's BioCorRx historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — BioCorRx

All Key Metrics — BioCorRx